Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRJ5LP)

Drug Name

Vasoactive intestinal peptide Drug Info

Synonyms

CCRIS 7231; Vasoactive intestinal polypeptide; Vasointestinal Peptide; Vasoactive intestinal peptide, synthetic porcine; SCHEMBL3041046; GTPL1152; VIP (Vasoactive Intestinal Peptide); LS-174653; VIP

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Phase 2	[1]
Pulmonary arterial hypertension	BB01.0	Phase 2	[1]

Cross-matching ID

PubChem CID: 53314964
CAS Number: CAS 37221-79-7
TTD Drug ID: DMRJ5LP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Vasoactive intestinal polypeptide receptor 1 (VIPR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PACAP-27	DMB26IK	Discovery agent	N.A.	Investigative	[3]
helodermin	DMIUABO	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vasoactive intestinal polypeptide receptor 1 (VIPR1)	TTCL30I	VIPR1_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT00464932) Vasoactive Intestinal Peptide in COPD. U.S. National Institutes of Health.
2	Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
3	A systematic comparison of intracellular cyclic AMP and calcium signalling highlights complexities in human VPAC/PAC receptor pharmacology. Neuropharmacology. 2006 Nov;51(6):1086-98.
4	Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: pharmacological, functional and molecular properties. Eur J Pharmacol. 1996 Apr 29;302(1-3):207-14.